characteristics.text: SAMN33411801
characteristics.characteristic: External Id
characteristics.text: Biomedical Engineering, Columbia University
characteristics.characteristic: INSDC center name
characteristics.text: 2023-03-11T00:00:00Z
characteristics.characteristic: INSDC first public
characteristics.text: 2023-03-11T01:16:29.857Z
characteristics.characteristic: INSDC last update
characteristics.text: SRS16861508
characteristics.characteristic: INSDC secondary accession
characteristics.text: live
characteristics.characteristic: INSDC status
characteristics.text: Generic
characteristics.characteristic: NCBI submission model
characteristics.text: Generic.1.0
characteristics.characteristic: NCBI submission package
characteristics.text: SRS16861508
characteristics.characteristic: SRA accession
characteristics.text: A172, T98G and U87MG cells
characteristics.characteristic: cell line
characteristics.text: Human glioblastoma brain cancer cells expressing dCas9-KRAB and further transduced to express single-guide RNAs against 522 protein kinases or non-targeting control single-guide RNAs.
characteristics.characteristic: cell type
characteristics.text: Homo sapiens
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: organism
characteristics.text: A172, T98G and U87MG cells
characteristics.characteristic: source_name
characteristics.text: sciPlexGxE_2
characteristics.characteristic: title
characteristics.text: Cells were treated with increasing doses of the small molecules Lapatinib, Nintedanib, Trametinib, ZSTK474 or dmso vehicle control.
characteristics.characteristic: treatment